• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Lithium Exposure: What are the Risks During Pregnancy?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Perinatal risks related to lithium exposure remains unclear
  • Fornaro et al. (American Journal of Psychiatry, 2019) sought to determine the efficacy and the safety of lithium use during pregnancy

METHODS:

  • Systematic review and random effects meta-analysis
  • Inclusion criteria
    • Case-control, cohort, and interventional studies
    • Studies that reported quantitative data on the safety or efficacy of lithium treatment during pregnancy and the postpartum period
    • Review articles and series <10 subjects were excluded
  • Primary outcomes
    • Safety: any congenital anomaly
    • Efficacy: mood relapse prevention
  • Secondary outcomes
    • Other safety outcomes during pregnancy and postpartum
    • Major cardiac malformations: were defined VSD and Ebstein’s anomaly, but excluded ASD

RESULTS:

  • 13 studies | 1,349,563 pregnancies
  • Lithium prescribed during pregnancy was associated with higher odds of
    • Any congenital anomaly
      • Prevalence: 4.1%
      • Odds ratio (OR): 1.81 (95% CI, 1.35 to 2.41)
      • Number needed to harm (NNH): 33 (95% CI, 22 to 77)
    • Cardiac anomalies
      • Prevalence: 1.2%
      • OR: 1.86 (95% CI, 1.16 to 2.96)
      • NNH: 71 (95% CI, 48 to 167)
  • Lithium exposure during the first trimester was associated with higher odds of spontaneous abortion
    • Prevalence: 8.1%
    • OR: 3.77 (95% CI, 1.15 to 12.39)
    • NNH: 15 (95% CI. 8 to 111)
  • Comparing lithium-exposed with unexposed patients with affective disorders
    • There was still a significant increase in risk of
      • Any malformation (exposure during any pregnancy period or the first trimester)
      • Cardiac malformations (exposure during the first trimester)
    • There was no increase in risk for
      • Spontaneous abortion (exposure during the first trimester)
      • Cardiac malformations (exposure during any pregnancy period)
    • When cardiac anomalies were restricted to the first trimester, risk was significantly increased
      • OR: 1.75 (95% CI, 1.08 to 2.84)
  • Lithium was more effective than no lithium in preventing postpartum relapse
    • OR: 0.16 (95% CI, 0.03 to 0.89)
    • Number needed to treat: 3 (95% CI, 1 to 12)
  • Mothers with serum lithium levels <0.64 mEq/L and dosages <600 mg/day had more reactive newborns without an increased risk of cardiac malformations

CONCLUSION:

  • Neonatal risks associated with lithium exposure in pregnancy are low
    • Risk is higher for the first trimester or with higher-doses of lithium
    • Risk needs to be balanced against benefit of medication and potential for other confounding factors including behavioral factors
  • The authors suggest that
    • Preconception counseling would be of value
    • Maintain lowest therapeutic range throughout pregnancy (especially during the first trimester)

Want to receive one research summary daily to your email and/or text? Get ObGFirst! Tap Here »


Learn More – Primary Sources:

Lithium Exposure During Pregnancy and the Postpartum Period: A Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Screening for Perinatal Depression
Does Lithium Exposure Decrease Risk for Dementia?
Can Transcranial Magnetic Stimulation Safely Aid Women with Major Depression in Pregnancy?
Do Antidepressants During Pregnancy Increase Autism Risk?
Labeling of Drugs in Pregnancy and Lactation: What Happened to A, B, C, D, and X?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site